Adding trastuzumab to chemotherapy for patients with early-stage HER2-positive breast cancer reduces the absolute 10-year risk of recurrence by 9% and mortality by 6.5% (relative reduction of approximately a third) [1]. The gene discussed is ERBB2; the disease is breast carcinoma.